Loading...
•
Dec 31, 2024
Sage Q4 2024 Earnings Report
Sage reported a decrease in net loss and an increase in collaboration revenue for the fourth quarter and full year 2024.
Key Takeaways
Sage Therapeutics reported a net loss of $95.8 million for the fourth quarter of 2024, an improvement from $32.7 million in the same period of 2023. Collaboration revenue from ZURZUVAE significantly increased to $11.4 million in Q4 2024, up from $0.8 million in Q4 2023, indicating strong initial growth for the new treatment. The company also saw a substantial increase in ZURZUVAE shipments, with nearly 2,500 prescriptions delivered in Q4 2024.
ZURZUVAE collaboration revenue reached $11.4 million in Q4 2024, a significant increase from $0.8 million in Q4 2023.
Net loss for Q4 2024 was $95.8 million, compared to $32.7 million in Q4 2023.
Nearly 2,500 ZURZUVAE prescriptions were shipped in Q4 2024, representing a 21% increase from Q3 2024.
Cash, cash equivalents, and marketable securities stood at $504 million as of December 31, 2024, with a cash runway expected to support operations to mid-2027.
Revenue by Segment
Forward Guidance
Sage Therapeutics anticipates its existing cash, cash equivalents, and marketable securities, along with anticipated funding from collaborations and estimated revenues, will support operations until mid-2027. The company expects overall operating expenses to decrease in 2025 due to reductions in R&D and G&A, pipeline prioritization, and cost savings from the October 2024 reorganization.
Positive Outlook
- Existing cash, cash equivalents, and marketable securities, combined with anticipated funding and estimated revenues, are expected to support operations to mid-2027.
- Overall operating expenses are anticipated to substantially decrease in 2025 compared to 2024.
- Reductions in R&D and G&A expenses are expected in 2025.
- Cost savings from the October 2024 reorganization are expected to be realized, with the first full quarter of savings in Q1 2025.
- ZURZUVAE joint commercialization investment will increase in 2025, indicating continued focus on market expansion.
Challenges Ahead
- Commercialization efforts for ZURZUVAE may not be successful, potentially failing to generate expected revenues or achieve goals.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...